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Introduction
All organisms show biologically driven declines in motor 
function as they age and these declines are closely linked 
to mortality (1, 2). In humans, these declines manifest as 
the frailty syndrome, which is defined by the overlapping 
characteristics of low physical activity, slowed motor 
performance, weakness, fatigue or exercise intolerance, and 
unintentional weight loss (3). Physiologically, frailty reflects a 
lowered resistance to stressors resulting from multi-systemic 
decline. Clinically, frailty is associated with diagnoses of 
sarcopenia, the age-related loss of muscle mass and strength, 
and osteoporosis, the loss of bone mass and the deterioration of 
bone tissue (4). When they occur together, the syndrome may 
be referred to as “osteosarcopenia” (5). Moreover, interactions 
between bone and muscle through multiple physiological 
pathways, including hormonal and inflammatory pathways, are 
thought to result in the frailty syndrome (6). 
As it has done every year since 2014, the International 
Conference of Frailty and Sarcopenia Research (ICFSR) Task 
Force brought together researchers from academia and industry 
to discuss challenges and opportunities for managing frailty and 
sarcopenia. In 2020 the Task Force met in Toulouse, France, 
where it focused attention on emerging interventions to manage 
fracture and osteoporosis in frail older adults. This population 
group has often been excluded from recent osteoporosis drug 
trials due to comorbidities and polypharmacy, despite the fact 
that they may potentially benefit more from a treatment since 
they are more likely to have falls, fractures, disability and a 
poor prognosis. 
Associations of frailty with osteoporosis, fragility fracture, 
and malnutrition
Bone fragility caused by osteoporosis occurs commonly in 
older adults and results in increased risk of fragility fracture 
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(7). A systematic review of worldwide studies estimated that 
9 million osteoporotic fractures occurred in 2000, resulting in 
substantial disability, morbidity, and mortality (8). However, 
osteoporosis may not be diagnosed until an individual has 
experienced multiple fragility fractures; and studies show that 
after diagnosis,  treatment for osteoporosis is not routinely 
given in older adults and adherence to medical regimens is poor 
(9). 
One of the most common and disabling fractures sustained 
by older persons is hip fracture, which may result in long-term 
mobility impairment, reduced ability to care for oneself or 
participate in everyday activities, pain, anxiety, and depression 
(10). Nutrition plays an important role in bone health and 
sarcopenia (11, 12), and malnutrition is common in individuals 
with hip fracture (13). Sarcopenia is also associated with an 
increased rate fractures in older adults (14, 15). 
Most patients with hip fracture complain of pain and 
resulting functional limitations six months after the fracture 
(16), which can lead to a vicious cycle of self-medication and 
mistrust of clinicians (17). Recovery from hip fracture may be 
delayed in the presence of sarcopenia (18), and hip fracture may 
be particularly disabling in individuals with frailty (19). Nearly 
30 years ago, Marottoli and colleagues showed that physical 
function before the fracture predicts functional recovery (20). 
Comorbidities, fear of falling, and other age-related conditions 
may further exacerbate hip fracture and its associated functional 
consequences (21, 22). Moreover, individuals over age 80 
years, in addition to meeting the frailty phenotype proposed 
by Fried and colleagues (i.e., weight loss, fatigue, slow gait 
speed, weakness, sedentary lifestyle), often live alone, and 
often experience cognitive decline (23); thus they need special 
management for frailty. However, frail older persons are often 
excluded from clinical trials of fragility fracture interventions, 
in part because of comorbidities, sarcopenia, cognitive 
impairment, and polypharmacy (24).
The substantial impact of fragility fractures on functioning in 
frail older persons thus requires dedicated and multidisciplinary 
care pathways, which have been shown to improve quality of 
life and physical function and limit excessive costs (25, 26). 
Intensive interventions including exercise and physical therapy 
immediately following hip fracture is essential. Preventive 
strategies also need to be widely implemented, including 
early identification of those at risk, increased prescribing of 
bone loss prevention treatments, and the introduction of care 
models based on the comprehensive geriatric assessment and 
personalization of interventions. Recently multidisciplinary, 
evidence-based guidelines for the management of osteoporosis 
and fragility fractures have been published (27–29).  
Given the association of poor nutrition with sarcopenia and 
frailty (30, 31), assessment of the nutritional status of older 
adults provides a potential pathway to interventions that could 
delay or prevent these disabling conditions of aging (32). 
The Mini Nutritional Assessment (MNA) is a tool designed 
to rapidly assess nutritional status though a series of simple 
measurements and brief questions (33). The MNA has been 
validated in frail older persons (34) and in community-dwelling 
older adults, demonstrating that frailty and malnutrition are 
distinct but related conditions (35–37). 
Using the MNA short form (MNA-SF), investigators showed 
that poor nutrition in combination with frailty was associated 
with an increased prevalence and incidence of poor functional 
outcomes in the Singapore Longitudinal Aging Study (32). 
In cancer patients, a low MNA score combined with a high 
Groningen Frailty Index (GFI) score was associated with an 
increased mortality risk (38). MNA score has also been used as 
a prognostic factor of adverse outcomes after hip fracture (39). 
Yet while there is mounting evidence about the importance of 
stratifying research populations for frailty, impaired nutritional 
status at baseline has been associated with greater benefits from 
the interventions (40, 41). The new ESPEN guidelines on the 
treatment of malnutrition in older people include a section on 
hip fracture, with the recommendation to incorporate nutrition 
intervention into a multidisciplinary approach (42). 
As a screening tool in outpatients, the MNA-SF has been 
shown to have a sensitivity of 71.2% and specificity of 92.8% 
(AUC 0.906) for the detection of frailty, and a 45.7% sensitivity 
and 78.3% specificity (AUC 0.687) for the detection of pre-
frailty (43). In hospitalized patients, the MNA-SF predicted 
frailty with good sensitivity but only marginal specificity (44). 
There is no evidence that the MNA can be used as an outcome 
measure in trials. 
Pharmacological treatment for osteoporosis, sarcopenia, 
and frailty 
Better targeting of therapeutic interventions for the 
management of osteoporosis starts with diagnosis, identification 
of risk factors, and an assessment of fracture risk (45). The 
International Osteoporosis Foundation and European 
Society for Clinical and Economic Aspects of Osteoporosis 
and Osteoarthritis published guidance for the diagnosis and 
management of osteoporosis in 2013, and recently updated 
such guidance (46). Diagnostic criteria for sarcopenia have also 
been recommended by other different groups.  The European 
Working Group on Sarcopenia in Older People (EWGSOP) 
published a definition in 2010 and updated it in 2019 based on 
a better understanding of the condition (47, 48); and the ICFSR 
published guidelines on the management of sarcopenia in 2018 
(49). In 2017, sarcopenia also was assigned a diagnostic code 
in the International Classification of Diseases, Tenth Revision, 
Clinical Modification (ICD-10-CM) code book, indicating 
recognition of sarcopenia as a separately reportable disease 
condition for clinical practice and drug development (50). 
A fracture may trigger a downward spiral of recurrent 
fractures known as the “fracture cascade” (51). A study in 
Iceland showed that the first fracture dramatically increases the 
risk of a subsequent fractures, particularly during the first year 
following the first event and regardless of the site of it. The 
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authors concluded that treatment should be started immediately 
to prevent recurrence of the problem (52). Bone fragility, 
determined by assessing bone mineral density (BMD) at the hip 
or spine by DXA scan, is associated with high fracture risk (53), 
suggesting that restoring bone density may significantly reduce 
the risk of a second fracture. Low muscle strength and low 
physical function (sarcopenia) also increase the risk of injurious 
falls and fractures after a first hip fracture (54).
Several bone-forming drugs are clinically available, 
including anti-resorptive agents such as denosumab (55–57); 
romosozumab, a monoclonal antibody that both increases 
bone formation and inhibits bone resorption (58, 59); anabolic 
agents such as teriparatide (60) and abaloparatide (61–63); 
biphosphonates such as alendronate and zoledronic acid (64); 
and myostatin inhibitors, which are also under research as 
potential drugs to treat sarcopenia (65, 66). 
Optimal treatment of osteoporosis may require sequential 
or combination therapies, for example starting with a bone 
forming agent then add an antiresorptive agent for maintenance. 
For example, in the phase 2 FRActure study in postmenopausal 
woMen with ostEoporosis (FRAME), romosuzumab followed 
by denosumab reduced the risk of fracture in postmenopausal 
women (67). Other sequential regimens that have shown 
promise in lowering fracture risk and/or increasing bone 
density include romosozumab followed by alendronate (68), 
abaloparatide followed by alendronate (69,70), and combination 
denosumab/teriparatide followed by denosumab alone (71).  
Preventing frailty and its consequences through nutrition 
and exercise 
The concept of frailty facilitates a better understanding of 
heterogeneity in the older population and promotes study of 
the aging process. It provides a possible target for preventive 
measures aimed at reducing the functional decline and the 
occurrence of negative events such as falls and fractures (72, 
73). Frail patients present with weakness, fatigue, a sedentary 
lifestyle and mobility impairment. They may have anorexia and 
recent weight loss. All of these clinical signs increase the risk 
of falls and fractures. They are also accessible to interventions 
such as nutritional management and/or physical exercise 
(focused on strength training and balance), which reduce the 
risk of falling (74, 75).
Several mechanisms responsible for both growth and decline 
of muscles and bones are shared. It has been hypothesized 
that pharmacological, nutritional, and/or exercise-based 
interventions may also overlap and provide mutual/dual benefits 
(76). For example, both skeletal muscle and bone respond to 
treatment with androgens, and exercise is an essential element 
of treatment regimens for osteoporosis, sarcopenia, and frailty. 
Malnutrition plays an important role in the development of both 
sarcopenia and frailty (31). Decreased dietary protein intake 
has been shown to result in decreased lean muscle mass in the 
Health Aging and Body Composition (ABC) Study (77). The 
Vitality, Independence and Vigor Study (VIVE2) showed that 
a high protein, high vitamin D nutritional supplement added to 
a physical activity intervention led to improvements in  muscle 
density and a loss of intermuscular fat in mobility-limited 
older adults (78), although these benefits seemed insufficient 
to improve functional measures such as gait speed (79). Other 
studies have shown that a combination of resistance exercise 
and increased protein intake prevented muscle wasting in older 
adults (80, 81). 
Obesity is known to contribute to functional declines 
and frailty in older adults. Sarcopenia in combination with 
obesity – a condition known as sarcopenic obesity – increases 
Table 1
Screening Tool for the “Integrated Care for Older Persons” (ICOPE)
Declines in Intrinsic Capacity Subdomains Tests
Cognitive Decline 1. Remember three words: Flower, door, rice (for example)
2. Orientation in time and space: What is the full date today? Where are you now (home, clinic, etc.)?
3. Recalls the three words?
Limited Mobility Chair rise test: Rise from chair five times without using arms. Did the person complete five chair rises 
within 14 seconds?
Malnutrition 1. Weight loss: Have you unintentionally lost more than 3 kg over the last three months?
2. Appetite loss: Have you experienced loss of appetite?
Visual Impairment Do you have any problems with your eyes: Difficulties in seeing far, reading, eye diseases or currently 
under medical treatment (e.g., diabetes, high blood pressure)?
Hearing Loss Hears whispers (whisper test) or 
Screening audiometry result is 35 dB or less or Passes automated app-based digits-in-noise test
Depressive Symptoms Over the past two weeks, have you been bothered by
• Feeling down, depressed or hopeless?
• Little interest or pleasure in doing things?
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the risk of functional decline through multiple synergistic 
pathways. Intervention strategies to combat sarcopenic obesity 
include weight reduction, calorie restriction, and exercise. 
Pharmacological strategies may also prove useful (82). Weight 
reduction through calorie restriction has been shown to have 
positive effects on longevity, yet it also may result in a loss of 
fat and lean mass and bone density (83, 84). In a study of older 
frail obese adults, an intervention that combined weight loss 
and aerobic plus resistance exercise, Villareal and colleagues 
showed that in comparison to either approach alone, the 
combination resulted in greater physical function and aerobic 
capacity and attenuated the loss of bone mineral density (85, 
86). 
The mechanisms by which dietary changes and exercise 
influence muscle and bone provide clues that may help design 
better and more targeted intervention strategies. For example, 
evidence implicates age-related declines in muscle insulin-like 
growth factor 1 (IGF-1) in sarcopenia; and both exercise and 
injury increase IGF-1, IGF-1 receptors, and IGF-1 activated 
signaling pathways. Aging muscle may have less ability to 
synthesize IGF-1 or may be resistant to IGF-1, and aging may 
also be associated with attenuation of the ability of exercise to 
induce IGF-1 (87).  
A small study of healthy older women fed with a low-protein 
diet for 10 weeks showed a decline in both muscle mass and 
IGF-1 (88). More than 20 years ago, Rizzoli and colleagues 
showed that protein supplementation in frail individuals 
post hip fracture restored levels of IGF-1 in the plasma and 
attenuated loss in bone mineral density compared to placebo 
(89). Supplementation with selenium and coenzyme Q10 have 
also been shown to increase levels of IGF-1 in older adults (90). 
Skeletal muscle cells express the vitamin D receptor (VDR), 
and low levels of vitamin D have been associated with lower 
muscle strength, mobility impairments, and disability (91).  In 
mobility-impaired older women, vitamin D supplementation 
increased VDR expression and improved skeletal muscle 
fiber size (92). However, another study in older adults with 
low baseline levels of serum 25(OH)D showed that while 
supplementation increased serum levels to more normal levels, 
there was no effect on lean mass, lower-extremity power, or 
strength (93). 
Nutritional supplements that target inflammation have also 
been proposed as a strategy for improving muscle function in 
older adults. For example, omega-3 fatty acids derived from 
fish oil have also been shown to slow decline in muscle mass 
and function in older adults (94). However, a recent clinical 
trial, the ENabling Reduction of low-Grade Inflammation in 
SEniors (ENRGISE) Pilot study, which tested the efficacy of 
fish oil and the angiotensin receptor blocker losartan in older, 
mobility-impaired adults, showed no improvement of walking 
speed or serum level of the inflammatory marker IL-6 (95).  
Demonstrating the efficacy of nutritional interventions 
is challenging for many reasons, including the difficulty of 
determining whether the baseline level of dietary intake is 
inadequate and capturing subtle effects of change from baseline. 
These challenges are exacerbated when nutritional interventions 
are superimposed on other interventions. 
Designing clinical trials to target bone fracture in frail older 
adults
The burden of fracture is expected to increase worldwide as 
the population ages, yet few trials have assessed the benefit of 
treatments in the oldest old and even less in the frail population 
(96, 97). Thus, fracture prevention and optimizing bone health 
represent important public health goals. Interventions that target 
the frail population offer the potential for the greatest benefit, 
as was demonstrated in a study by Rolland and colleagues, 
which tested the ability of strontium ranelate to reduce vertebral 
fractures in osteoporotic women, independently of frailty status 
(98). Beyond pharmacological interventions, nutrition and 
exercise have been shown to act synergistically to improve 
bone and muscle health and thus should be incorporated into 
randomized clinical trials (99).
To increase the efficiency and maximizing learnings 
from clinical studies, sponsors and researchers should use 
harmonized protocols with similar outcome measures. The 
ICFSR Task Force suggested the following:  
Possible Study Design
 The placebo-controlled, parallel-arm, double-blind trial is 
the gold standard for assessing efficacy and effectiveness. Other 
elements of an optimal trial design include:
• A long run-in phase before initiating treatment, during which 
activity diaries could be monitored and dietary inadequacies 
or anemia corrected to ensure a stable baseline.
• 2 x 2 designs for studies testing multimodal approaches such 
as resistance exercise and/or combination of resistance and 
aerobic exercise and nutrition.
• Using assessment time points that have been harmonized 
with other studies to enable data pooling and meta-analyses 
of data.
• Use the gold standard of collecting falls incidence using 
monthly calendars.
• At least one-year of follow up. If studies aim to target bone 
fracture or prevent the progression from pre-sarcopenia to 
sarcopenia, long follow-up will be necessary.
Proposed Outcomes  
• Primary outcome: fragility fractures at 24 months (hip and 
spine). 
• Secondary outcomes: 
o Physical performance and disability as measures of 
functional decline
o Injurious falls
o Patient-reported outcomes,  including mobil i ty 
assessments and quality of life
o Nursing home admissions
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o Bone turnover biomarkers





Note that Fragility fractures or injurious falls as the primary 
outcome will require a very large sample size. Benefit of 
pharmacological treatment has also needed a large sample size.
Potential Target Population
• Patients with low BMD, high rate of falls (such as ≥2 self-
reported falls/year), and frailty.
• Inclusion criteria: ≥ 75 years old with osteoporosis defined 
by low BMD, FRAX, and/or history of osteoporotic fracture, 
and with frailty defined by variable proven predictive of falls 
(100). Patients in nursing homes and those with dementia 
should be included where possible.
• Exclusions:  Projected life expectancy < 2 years or estimated 
glomerular filtration rate < 30 mL/min/1.73 m2, individuals 
who are bedridden or who have contraindications related to 
the drug being tested
Design of Interventions 
Frailty is a complex syndrome requiring multidimensional 
interventions. Interventions should target two or more risk 
factors for falls. For example, polypharmacy and some specific 
medications have been associated with increase fracture 
risk (101, 102). The European Geriatric Medicine Society 
(EuGMS) Task and Finish group on Fall-Risk-Increasing 
Drugs (FRIDs) recently proposed practical recommendation 
and strategies to reduce the use of FRIDs (103). The increase 
risk of falls related to the use of psychotropics drugs (104), 
cardiovascular drugs (105) and other medications (106) is 
now well-known.  As the field of geroscience continues to 
emerge, it may become possible to target aging itself (107). For 
example, cellular senescence represents a promising therapeutic 
paradigm for potentially preventing or even reversing age-
related osteoporosis and simultaneously treating multiple aging 
comorbidities (108).
Multidomain interventions for preventing falls in older 
people living in the community typically include physical 
activity (strength and balance classes with walking practice), 
and deprescribing. A systematic review and meta-analysis 
concluded that such multidomain interventions may reduce the 
rate of falls and recurrent falls, although the impact on fracture 
reduction has not been clearly demonstrated (109). 
To test an osteoporosis drug in combination with 
a multidomain intervention, four parallel groups are 
recommended: 1) osteoporosis drug alone, 2) multidomain 
intervention alone, 3) osteoporosis drug plus multidomain 
intervention, 4) placebo or active comparator. 
The Multidomain Alzheimer’s Prevention Trial (MAPT) 
study is an example of a multidomain trial in frail older adults 
(110). This three-year, multicenter, randomized, placebo-
controlled superiority trial enrolled community-dwelling 
persons aged 70 or older with spontaneous memory complaints, 
absence of dementia, and limitations in one instrumental 
activity of daily living or slow gait speed. They were randomly 
assigned to one of four groups: 1) a multidomain intervention 
comprising cognitive training, physical activity, and nutritional 
counseling plus omega-3 polyunsaturated fatty acids with a 
total daily dose of 800 mg docosahexaenoic acid and 225 mg 
eicosapentaenoic acid, 2) the multidomain intervention plus 
placebo, 3) omega-3 polyunsaturated fatty acids alone, or 4) 
placebo alone. The trial was registered with ClinicalTrials. gov 
(NCT00672685).   
Conclusions and next steps
The ICFSR Task Force reached several conclusions. First, 
it recognized that the traditional care system is inadequate for 
dealing with complex health disorders of aging such as frailty, 
where multidisciplinarity is required (111, 112). Cognitive 
impairment is often associated with frailty and must be taken 
into consideration (113, 114). The links between frailty and 
cognition are now well described (115–117) and integrated care 
like the ICOPE program have to be promoted to prevent and 
treat fractures in frail older persons (118–121).
Second, the Task Force suggested that reducing fracture risk 
among older adults requires first intervening with a powerful 
agent to restore the strength of bone, and then switching to an 
anti-resorptive agent to maintain bone health. The need for 
treatment is especially true after a first major hip fracture. The 
high cost of many of these drugs imposes a barrier to such 
an approach and payers will require studies that document 
efficacy; yet fractures themselves are costly and health 
economics studies show that bone forming agents are cost-
effective even over short time periods.  Combination therapies 
were also recommended, not just for treating the bone but 
for other factors as well, particularly in individuals who are 
frail. Benefits of these drugs in frail populations with high 
risk of fracture, short life expectancy, and high risk of adverse 
events such as nursing home residents should be investigated. 
One problem is that these frail older adults often take many 
drugs due to co-morbidities, including cognitive impairment, 
undernutrition, depression, and loneliness, raising questions 
about the value of further adding drugs to treat osteoporosis 
versus decreasing drug consumption in frail older adults. 
Advances in the field of geroscience may help in the future 
to answer these questions by introducing new biomarkers and 
better targeted therapies (122–124). 
Third, the Task Force noted that while pathophysiology 
of bone fracture is the same in frail and non-frail adults, 
the mechanisms that lead to bone fracture – poor balance, 
sarcopenia, poor physical performance, sedentary lifestyle, 
and poor nutritional status – differ. Given these differences, 
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specific recommendations may be needed for interventions 
in people who are frail, for example by more routinely 
adopting multidimensional and comprehensive interventions 
(125). To develop these interventions, more studies are needed 
in people who are frail and old. In addition,  high-quality 
research is needed to confirm the role of nutrition in reversing 
or preventing frailty and adverse outcomes in frail persons 
(126, 127). Moreover the ICOPE program developed by 
WHO appears to be most useful for the frail older adults with 
osteoporosis to maintain Intrinsic capacities, monitor functions 
with ICOPE MONITOR (119) and prevent further disabilities 
(Table 1).
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